Article Text

Download PDFPDF

LO-041 Severe thrombocytopenia is associated with adverse pregnancy outcomes in obstetric antiphospholipid syndrome
  1. Jiayang Jin and
  2. Chun Li
  1. Department of Rheumatology and Immunology, Peking university People’s Hospital, China


Background Thrombocytopenia is a common complication of antiphospholipid syndrome (APS). It is a main concern for hemorrhage risk on the current standard treatment of low dose aspirin (LDA) and low molecular weight heparin (LMWH) in obstetric APS (OAPS). This study assesses the possible relationship between the different levels of thrombocytopenia and adverse pregnancy outcomes (APOs) in OAPS patients.

Methods A retrospective study was conducted at Peking University People’s Hospital, Beijing, China. The demographic, clinical, immunologic, and pregnancy outcomes of the OAPS patients were collected. Univariate and multivariate logistic regression analyses were applied to assess the association between APOs and thrombocytopenia, especially severe thrombocytopenia (<30×109/L).

Results A total of 206 participants were included in the analysis. There were 30 with mild to moderate thrombocytopenia (30–100×109/L) and 19 with severe thrombocytopenia (<30×109/L) among 176 OAPS patients in pregnancy. The rate of the hypocomplementemia in severe thrombocytopenia group (36.84%) was higher than that in the non-severe group (20.00%) and in control group (9.57%) (P = 0.005). Severe thrombocytopenia was associated with a higher APOs of OAPS, such as preterm delivery before 34 weeks (Model I: OR, 16.09; 95%CI, 3.69–70.10, P = 0.0002; Model II: OR, 10.33 ;95%CI, 2.02–52.88, P = 0.0051), uteroplacental insufficiency (Model I: OR, 3.35;95%CI, 1.14–9.85, P = 0.028; Model II: OR, 5.98;95%CI, 1.62–22.14, P = 0.0074), and gestational hypertension (Model I: OR, 5.26;95%CI, 1.16–23.82, P = 0.031; Model II: OR, 9.45;95%CI, 1.43–62.45, P = 0.0198), but not the mild to moderate thrombocytopenia after adjusting for demographic and laboratory factors. After adding medication adjustments, these factors above become insignificant (p > 0.05).

Conclusions The risk of APOs depends on the different levels of thrombocytopenia in OAPS patients. Only severe thrombocytopenia is associated with adverse pregnancy outcomes. The effective OAPS treatments may improve pregnancy outcomes.

  • antiphospholipid syndrome
  • severe thrombocytopenia
  • preterm delivery before 34 weeks

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.